Writing a Regulatory Strategy Section SBIR Reviewers Respect
What NIH and NSF reviewers actually look for in the regulatory portion of an SBIR application — and the phrases that cost you points.
SBIR reviewers score regulatory strategy whether or not you give them much to score. A vague “we will pursue FDA clearance” line reads as a gap, not a plan. The good news: a credible regulatory section is mostly about specificity, and specificity is learnable.
What reviewers are checking for
They want evidence that you understand the path your device has to walk. Concretely, that means naming the likely pathway, naming a predicate or class, and showing you know what testing the pathway implies. A reviewer reading your application is asking a simple question: does this team know what it’s getting into?
The phrases that cost you points
- “We will figure out the regulatory pathway.” This signals you haven’t started.
- “FDA approval” for a 510(k) device. 510(k) is a clearance, not an approval. The vocabulary slip tells a knowledgeable reviewer you’re new.
- “No significant regulatory risk” with nothing to back it. Unsupported confidence reads worse than acknowledged uncertainty.
What a strong paragraph contains
A reviewer-respecting regulatory section names four things: the device classification and product code, the regulatory pathway and why, a representative predicate or comparable device, and the testing categories you anticipate. Even a few sentences hitting those points outperform a paragraph of hedged generalities.
Build it once, reuse it everywhere
The same regulatory analysis feeds your Specific Aims, your Commercialization Plan, and your investor conversations. Doing the classification work early means you’re not reinventing it under deadline pressure — and it’s exactly the grant-ready language RegReady packages into every report.